dopa-induced dose-onset dyskinesia. For these reasons, she was referred to us for STN stimulation.
When the patient presented to us the total duration of the off-medication period reached 50% of the day. She complained that the BDMD always appeared after every dose of levodopa.
Presurgical Evaluation. During 2 days of observation, we confirmed that the BDMD occurred at 15 to 20 minutes after every dose of levodopa at 100 mg and lasted for approximately 15 minutes, while the intervals from the previous dose of levodopa varied in the range from 2.5 to 8 hours (Fig. 1) . The severity of the BDMD was variable, and the BDMD after the first dose of levodopa in the early morning was apparently most severe (Fig. 1B, Table 1 ). Exacerbation of the PD symptoms, particularly the tremor and rigidity, which predominated in the lower extremities, was noticeably worse during the BDMD than during the wearing-off period. The motor (Part III) score on the UPDRS was increased during the BDMD by 188% from the score during the best on-medication motor condition (on period) and by 44% from the score during the wearing-off motor deterioration (off period). The BDMD was followed by levodopa-induced dose-onset dyskinesia, which consisted of dystonic posture and pain in the left lower extremity (Fig.  1 ). The temporal relationship between the BDMD and dyskinesia was uniform, the onset and peak of the BDMD always preceded those of the dyskinesia by 15 to 20 minutes. These clinical findings were consistent with the characteristics of BDMD described in the literature. 12 It was impossible to attribute such short-lived motor deterioration to a continuation of wearing-off or end-of-dose motor deteriorations, since it occurred abruptly and invariably after every dose of levodopa, despite varying intervals between doses. Surgery and Postsurgical Course. The patient underwent implantation of electrodes (Model 3387, Medtronic, Inc.) and pulse generators for deep brain stimulation of the STN bilaterally. The PD symptoms were greatly improved by bipolar STN stimulation, especially during the off periods, at intensities ranging from 2.0 to 2.5 V (pulse width 180 sec, frequency 135 Hz) during the follow-up period. Subsequent to the initiation of STN stimulation, the doses of medication were reduced to 200/20 mg levodopa/dopa-decarboxylase, 750 g pergolide mesylate, and 10 mg selegiline hydrochloride per day. The medications were not completely withdrawn, because the patient reported some motor deterioration in the afternoon (lasting approximately 30 minutes). We confirmed that the BDMD was still induced by every dose of levodopa at 100 mg if the STN stimulation was kept turned off, and was immediately attenuated when the STN stimulation was turned on at intensities of Ͼ 1.8 V. Complete inhibition of the BDMD was achieved at intensities of Ͼ 2.5 V.
Standard follow-up evaluation at 6 months after surgery revealed that the UPDRS motor score was markedly improved by bilateral STN stimulation at an intensity of 2.0 V during the off period as well as the on period (78 and 75%, respectively; Table 1 pletely, leaving occasional slight and transient tremor in the lower extremities. The results of this evaluation confirmed that the immediate effect of STN stimulation on the BDMD had remained unchanged. The improvement had lasted and a "no off-medication" motor condition had been achieved at 12 months after surgery. We attempted a dopa challenge test (100 mg/10 mg levodopa/dopa-decarboxylase administered orally) at 14 months postoperatively, but BDMD did not occur. 12 reported BDMD occurring at 10 to 20 minutes after intake of levodopa and lasting for 10 to 20 minutes. Before their report, this phenomenon had been regarded as part of wearing-off or end-of-dose motor deterioration that continued until the next dose of levodopa. 3, 16 Although it has been suggested that BDMD might be common, 12 only limited experience of it has been described in the literature. 6, [11] [12] [13] 16 It appears possible that BDMD can be confused with coexisting levodopa-induced dose-onset dyskinesia. 12 In addition, most cases of BDMD have been detected previously under intentional pharmacological examinations, so it remains unknown how common BDMD might be in patients receiving standard levodopa medications. The present case suggests that a marked BDMD similar to the BDMD observed in intentional pharmacological examinations 12, 13 can also occur in patients receiving standard doses of levodopa medications.
Discussion
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Beginning-of-dose motor deterioration has been accounted for on the basis of the inhibitory effects of levodopa, which suppress endogenous dopamine release and synthesis through predominant activation of presynaptic dopamine autoreceptors. 19, 20, 22 This hypothesis implies that BDMD may be induced by a dose of levodopa that is insufficient to activate postsynaptic dopamine receptors. 12, 16 Management of BDMD may therefore be difficult in patients who are already receiving a relatively large dosage of levodopa, and when reducing the levodopa dosage in patients who are distressed by various side effects of the drug.
To the best of our knowledge, the present case demonstrates for the first time that BDMD can be inhibited by STN stimulation and further indicates the benefit of STN stimulation for managing the inhibitory effects of levodopa, if they are in fact responsible for the BDMD. In patients with PD, intraoperative microrecording has revealed that intravenous administration of apomorphine induces increased neuronal activities in both the STN 11 and the internal segment of the globus pallidus 7,13 during BDMD 11,13 and end-of-dose motor deterioration. 7 Such increased neuronal activities are also observed during wearing-off motor deterioration but are quantitatively more pronounced in that setting. 7, 11, 13 These findings suggest that motor deterioration in patients with PD is closely related to the activities of the basal ganglia, which result in an enhanced inhibitory input to the thalamus. Stimulation of the STN is suggested to suppress such abnormal neuronal activities underlying the PD symptoms 23 and to release the thalamus from excessive inhibition by the basal ganglia. 5, 21 It is possible that BDMD and wearing-off motor deterioration are inhibited by STN stimulation through the same mechanism. The precise process whereby STN stimulation can improve on-off motor fluctuation remains to be elucidated. Both presynaptic and postsynaptic mechanisms have been postulated. 15, 18 In a study on the interaction between deep brain stimulation and levodopa by Nutt et al., 18 the improvement effect of acute STN stimulation (when patients were awake during the day) on wearing-off motor fluctuation was inferred to be due to a reduction of off-drug disability, and not alterations in the levodopa pharmacodynamics. This may suggest that the action of STN stimulation may be independent of striatal dopamine transmission; namely, a postsynaptic mechanism is primary. In contrast, Nimura et al. 15 demonstrated that chronic STN stimulation can induce stabilization of the striatal synaptic dopamine concentrations based on an [ 18 F]fluorodopa positron emission tomography study, and levodopa-related wearing-off motor fluctuation may thus be attenuated. The results of the positron emission tomography study indicate that the stabilization induced by STN stimulation involves a presynaptic mechanism. This is assumed to incorporate the following two main processes: 1) activated output from the motor and premotor cortex, which is induced by relaxant output from the STN via the pallidothalamocortical pathway, tending to attenuate dopamine release in the striatum, and 2) restoration of autoregulation in striatal presynaptic dopamine release through a feedback input from the STN to striatal somatodendritic autoreceptors. We inferred that a reduction of levodopa dosage may also contribute stability of striatal dopamine transmission. These combined mechanisms could facilitate further improvement in dopa-induced motor fluctuations with chronic STN stimulation.
Conclusions
The present case confirms that STN stimulation can provide benefits in improving off-medication motor status through levodopa-like effects, through improving the onmedication motor status in patients who are intolerant to larger doses of levodopa, and through reducing the levodopa dose in patients who are distressed by various side effects of levodopa. 8 In addition, our observations suggest that STN stimulation has direct effects on some of the levodopainduced motor symptoms, such as BDMD. The combina- * ADL = activity of daily living; deter = deterioration; impr = improvement; Off = off period; On = on period; WO = wearing-off period.
† Percentage deterioration compared with wearing-off. ‡ Percentage improvement compared with before surgery. § No off-medication assessment was performed at the 12-month followup evaluation because a "no off-medication" condition had been achieved. tion of chronic STN stimulation and reduction in dosage of levodopa may contribute further by improving levodopainduced motor fluctuations through the stabilization of striatal dopamine transmission.
